SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 84 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $57,000 | -46.7% | 12,896 | -2.5% | 0.00% | 0.0% |
| Q3 2018 | $107,000 | +37.2% | 13,227 | +18.6% | 0.00% | 0.0% |
| Q2 2018 | $78,000 | -50.9% | 11,153 | 0.0% | 0.00% | -50.0% |
| Q1 2018 | $159,000 | +57.4% | 11,153 | -3.0% | 0.00% | +100.0% |
| Q4 2017 | $101,000 | -35.3% | 11,500 | -13.5% | 0.00% | -50.0% |
| Q3 2017 | $156,000 | +0.6% | 13,300 | +19.8% | 0.00% | 0.0% |
| Q2 2017 | $155,000 | -4.9% | 11,100 | -6.7% | 0.00% | -33.3% |
| Q1 2017 | $163,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |